What is Prevencio?
Prevencio operates at the intersection of artificial intelligence and clinical diagnostics, specializing in blood-based tests designed to identify cardiovascular disease with high precision. By leveraging patented algorithmic technology, the company provides healthcare providers with actionable insights that facilitate early detection of conditions such as coronary artery disease, while simultaneously predicting the risk of acute events like heart attacks and strokes. This approach not only improves patient outcomes but also optimizes healthcare resource allocation by reducing the necessity for invasive and costly diagnostic procedures. As a leader in the medical technology sector, Prevencio is effectively bridging the gap between complex biological data and clinical decision-making, establishing a new standard for preventative cardiovascular care.
How much funding has Prevencio raised?
Prevencio has raised a total of $675K across 1 funding round:
Angel/Seed
$675K
Angel/Seed (2016): $675K, investors not publicly disclosed
Key Investors in Prevencio
Prevencio
Undisclosed investor participating in the funding round.
What's next for Prevencio?
With this major enterprise-level funding, Prevencio is poised to accelerate its clinical validation programs and expand its commercial footprint. The strategic allocation of this capital will likely focus on enhancing the diagnostic sensitivity of its existing seven-test suite and broadening its reach within the global healthcare ecosystem. By prioritizing the integration of its AI-driven solutions into standard clinical workflows, the company aims to solidify its market position as a primary provider of predictive cardiovascular analytics. Future growth will be defined by the company's ability to scale its diagnostic infrastructure while maintaining the rigorous scientific standards required for widespread adoption among cardiologists and primary care physicians alike.
See full Prevencio company page
